Microsaic Systems (AIM: MSYS) said it has demonstrated and delivered an efficient automated production scaling methodology to fast-track drugs and vaccines to market.
The London-listed firm, which develops point of need mass spectrometry ("MS") instruments, has described the delivery of this first, real-time monitoring Process Analytical Technology ("PAT") MS solution aimed at scaling biotherapeutic production as a “significant milestone.”
Microsaic said its efforts to deliver this solution forms part of the recent G7 directive to deliver faster production of vaccines and treatments to manage both current and future pandemics.
Microsaic's micro-engineered and fully portable MS detector has been integrated with process control software, to provide continuous, real-time analysis of the biomanufacturing process, including the provision of additional data analytics for quality monitoring and assurance.
Explaining the solution to shareholders, Microsaic said live data transmitted via Internet of Things ("IoT") devices from the micro-engineered MS equipment enables the constant monitoring of production processes, to ensure high quality biological production output.
Additionally, the Company highlighted that a real-time alert system ‘allows rapid scaling to large volumes, reduces supervision costs, and accelerates vaccines and anti-cancer treatments through emergency and standard regulatory authorisation directly to patients.’
Shares in Microsaic Systems were trading 11.11% higher this morning at 0.25p.
In particular, the Biopharmaceuticals industry, which is a well-established and rapidly growing sector currently valued at c.$200bn, faces significant challenges around process robustness.
The Company stated that these challenges are particularly apparent within upstream processing, ‘which relies on fundamental biology and carries inherent product variability.’
Therefore, point-of-need MS would provide ‘timely and critical safety and quality assurance, as adverse effects would be identified earlier in the process and mitigated upstream,’ it said.
In addition, the analytical instrumentation market in upstream bioprocessing alone was projected to be worth circa $390 million in 2020. Microsaic said it believes that its ‘compact, easy-to-use, MS technology is well-positioned to access a share of this market, working with bioprocessing instrument providers and end-users in biopharmaceutical manufacturing alike.’
Commenting on the solution, Glenn Tracey, CEO of Microsaic Systems said: "As part of the recent G7 directive to deliver faster production of vaccines and treatments to manage the current and future pandemics, we are delighted to have achieved this significant milestone.
In just a short time we have demonstrated and delivered an efficient automated production scaling methodology to fast-track drugs and vaccines to market, at a lower cost of production and without manual human intervention, whilst maintaining consistent high quality.”
The Company informed investors that it is currently “not aware of any other technology that can simultaneously analyse small and large molecules as part of on-line production.”
“We expect to interface with end-user manufacturing processes during H2 of this year, and we look forward to augmenting our system with further advanced AI tools in our drive to remain at the cutting edge of technology in the Industry 4.0 era,” added Tracey.
Follow News & Updates from Microsaic Systems here: